On Mar. 17, 1995, the Food and Drug Administration (FDA) licensed Varicella Virus Vaccine, Live (VARIVAX {registered symbol}), manufactured and distributed by Merck (Rahway, New Jersey). This vaccine has been licensed for use in persons aged greater than or equal to 12 months.

The recommended dose for susceptible children aged 12 months-12 years is one 0.5 mL dose administered subcutaneously. The recommended dosage for susceptible adolescents aged greater than or equal to 13 years and adults is two 0.5 mL doses of vaccine 4-8 weeks apart.

The recommendations of the Advisory Committee on Immunization Practices on the use of varicella vaccine will be published. Reported by: Center for Biologics Evaluation and Research, Food and Drug Administration. National Immunization Program, CDC.